The Global Biosimilars Market to Register Growth at a

New York, USA, Oct. 20, 2022 (GLOBE NEWSWIRE) — The Global Biosimilars Market to Register Growth at a Massive CAGR of 21.54% During the Forecast Period (2022–2027) | DelveInsight

The biosimilars market is anticipated to surge in the coming years owing to the escalating burden of various chronic diseases such as arthritis, cancer, diabetes, among others worldwide, and the patent expiry of many successful biologics, and others.

DelveInsight’s Biosimilars Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies’ market shares, challenges, biosimilars market drivers, barriers, and trends, and key biosimilars companies in the market. 

Key Takeaways from the Biosimilars Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global biosimilars market during the forecast period.  
• Notable biosimilars companies include Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Amgen, Inc., Eli Lilly and Company, Novartis AG, Bioeq AG, Fresenius SE & Co. KGaA, STADA Arzneimittel AG, Gedeon Richter PLC, Celltrion Healthcare Co., Ltd., Samsung Bioepis. (Samsung Biologics), Coherus BioSciences, Viatris Inc., Shanghai Henlius Biotech, Inc., Biocon Limited, Biocad, mAbxience, Fujifilm Kyowa Kirin Biologics Co., Ltd., Alvotech, Sanofi,  Senju Pharmaceutical Co., Ltd., and others and several others are currently operating in the biosimilars market.
• On February 02, 2022, Samsung Bioepis Co. Ltd. received that Health Canada has approved ONTRUZANT® (also known as SB3), a biosimilar referencing Herceptin®i (Trastuzumab), for the treatment of adults with Early Breast Cancer (EBC), Metastatic Breast Cancer (MBC) and metastatic gastric cancer (MGC).
• In September 2021, Senju Pharmaceutical Co., Ltd. received approval to market the ophthalmic VEGF inhibitor “Ranibizumab BS intravitreal injection kit 10 mg/mL ‘Senju’” in Japan.
• In June 2021, Teva Pharmaceutical Industries Ltd….